Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Accum-E7
- Development stage
- Preclinical
- Lead developer
- Defence Therapeutics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular (preclinical Studies; Clinical Route May Be Similar)
01
Overview
Accum-E7 is an engineered protein-based cancer vaccine developed using the proprietary Accum technology platform. It targets the E7 oncoprotein of human papillomavirus (HPV), which is implicated in cervical cancer and other HPV-related malignancies. The vaccine is designed to enhance endosome-to-cytosol escape, promoting efficient antigen cross-presentation by dendritic cells and robust activation of cytotoxic CD8 T cells. In preclinical studies, Accum-E7 demonstrated both prophylactic and therapeutic efficacy against cervical cancer in mouse models—providing complete protection when used preventively and synergizing with immune checkpoint inhibitors (such as anti-PD-1, anti-CTLA4, and anti-CD47) to control established tumors. The mechanism relies predominantly on cross-presenting dendritic cells and CD8 T lymphocytes but also involves CD4+ and B cell responses. The vaccine has shown strong immunogenicity with no observed adverse effects in GLP animal studies[1][2][3][4].
- Brand names
- Accum-E7Accum-E-7Accum-E 7
- Other names
- Accum-E7Accum-E-7Accum-E 7aE7aE-7aE 7
02
Targets
E7 (Papillomavirus E6/E7 oncoproteins)
Beyond the preview
Go deeper on Accum-E7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accum-E7.